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Th1-mediated experimental autoimmune
encephalomyelitis is CXCR3 independent
Stephen J. Lalor and Benjamin M. Segal
Department of Neurology, Holtom-Garrett Program in Neuroimmunology, University of
Michigan, Ann Arbor, MI, USA
Drugs that block leukocyte trafficking ameliorate multiple sclerosis (MS). Occurrences of
opportunistic infection, however, highlight the need for novel drugs that modulate more
restricted subsets of T cells. In this context, chemokines and their receptors are attrac-
tive therapeutic targets. CXCR3, a Th1-associated chemokine receptor, is preferentially
expressed on T cells that accumulate in MS lesions and central nervous system (CNS)
infiltrates of mice with experimental autoimmune encephalomyelitis (EAE). Surprisingly,
mice genetically deficient in either CXCR3 or CXCL10 succumb to EAE following active
immunization with myelin antigens. EAE is mediated by a heterogeneous population of
T cells in myelin-immunizedmice. Hence, disease might develop in the absence of CXCR3
secondary to the compensatory action of encephalitogenic CCR6+ Th17 cells. However, in
the current study, we show for the first time that blockade or genetic deficiency of either
CXCR3 or of its primary ligand has no impact on clinical EAE induced by the adoptive
transfer of highly polarized Th1 effector cells. Our data illustrate the fact that, although
highly targeted immunotherapies might have more favorable side effect profiles, they are
also more likely to be rendered ineffective by inherent redundancies in chemokine and
cytokine networks that arise at sites of neuroinflammation.
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Introduction
Multiple sclerosis (MS), an inflammatory demyelinating disease
of the central nervous system (CNS), is the most common cause of
nontraumatic disability among young adults in the United States
and Europe. The majority of patients with MS present with a
relapsing remitting course, characterized by episodes of neuro-
logical disability separated by clinically quiescent periods. Dis-
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ease exacerbations correlate with focal breakdown of the blood–
brain barrier and infiltration of the CNS by circulating leukocytes,
as reflected by the appearance of gadolinium-enhancing lesions
on magnetic resonance imaging (MRI) scans of the brain and
spinal cord (SC) [1]. Drugs that block leukocyte trafficking have
been shown to ameliorate MS in phase 3 clinical trials. Hence,
gadolinium-enhancing lesions and clinical relapses are suppressed
by the administration of a mAb specific for the adhesion molecule,
α4 integrin, or by treatmentwith a sphingosine-1-phosphate recep-
tor modulator that prevents the egress of lymphocytes from lym-
phoid tissues [2, 3]. Sphingosine-1-phosphate receptors and α4
integrin are widely expressed on lymphocytes. The introduction of
reagents that antagonize those molecules represents a significant
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advance in MS therapeutics. However, there remains a need for
novel drugs that modulate more restricted subsets of T cells
in order to maintain clinical efficacy while perturbing protec-
tive immunity to the minimum extent possible. In this context,
chemokines and their receptors are attractive therapeutic targets
for the management of autoimmune disease.
It has long been recognized that the T cells that accumulate in
MS lesions are enriched for expression of the chemokine receptor
CXCR3 [4–6]. The ELR− CXC chemokines, CXCL9 and CXCL10,
which are ligands of CXCR3, are expressed by astrocytes and
microglia in spatial proximity to perivascular infiltrates [4, 7].
Similarly, CNS infiltrates of mice with experimental autoimmune
encephalomyelitis (EAE, widely used as an animal model of MS)
are characterized by a preponderance of CXCR3+ IFN-γ+ T cells
and upregulation of CXCL10 in adjacent astrocytes [8–11]. These
histopathological findings are consistent with the observation that
CXCR3 is expressed at high levels on CD4+ Th1 cells and can play
a critical role in their chemotaxis toward IFN-γ-inducible ELR−
CXC chemokines [12–14]. Therefore, it was unexpected that mice
genetically deficient in CXCR3 or CXCL10 have been shown to be
at least as susceptible to EAE as their immunocompetent coun-
terparts [15–17]. Furthermore, in several studies, antagonism of
CXCR3 or neutralization of CXCL10 in myelin-immunized wild-
type (WT) mice either had no clinical impact or, paradoxically,
exacerbated EAE [10,18,19].
In published studies on the role of CXCR3/ELR− CXC
chemokines in murine EAE, disease has primarily been induced
via active immunization with myelin antigens emulsified in com-
plete Freund’s adjuvant (CFA). Mice primed in this manner gen-
erate a heterogeneous pool of memory T cells including IFN-γ-
producing Th1 and IL-17-producing Th17 cells [20]. There is also
considerable diversity in the cytokine profiles of myelin-specific
T cells isolated from the blood and cerebrospinal fluid of individ-
uals with MS [21, 22]. We have previously shown that Th1 and
Th17 cells specific for the same myelin epitope induce clinically
indistinguishable forms of EAE by invoking the expression of dis-
tinct patterns of proinflammatory mediators and chemokines in
CNS tissues [23]. Consequently, Th1- and Th17-mediated EAE
respond differently to individual immunomodulatory therapies
[21, 24, 25]. In addition, there is accumulating evidence that
Th1 and Th17 cells employ distinct homing molecules to cross
the blood–brain barrier [13, 23, 26]. Therefore, the susceptibil-
ity of actively immunized mice to EAE in the absence of func-
tional CXCR3 interactions could be secondary to the compensatory
action of encephalitogenic Th17 cells, which have been reported
to accumulate in the CNS via a CCR6/CCL20-dependent path-
way [26]. We speculated that, under conditions where immune
responses are more uniform and highly polarized, the relative
importance of CXCR3/CXC chemokine interactions might vary
based on the Th bias of the peripheral autoreactive T-cell reper-
toire. In the current study, we used an adoptive transfer EAEmodel
to investigate whether CXCR3 and/or its ligands are viable ther-
apeutic targets for the treatment of inflammatory demyelinating
disease mediated by a Th1-skewed effector cell population.
Results
CXCR3−/− and CXCL10−/− mice are susceptible to MOG
induced EAE
Consistent with previous reports [15–17], we found that
CXCR3−/− and CXCL10−/− mice on a C57BL/6 background
readily succumb to EAE induced by active immunization with
myelin oligodendrocyte glycoprotein (MOG)35–55 in CFA. Fur-
thermore, disease incidence, the clinical course, and degree
of CNS infiltration did not differ significantly between knock-
out mice and their WT counterparts (Fig. 1A, B, E, and F).
Splenocytes and draining LN (dLN) cells harvested from MOG-
immunized WT, CXCR3−/− and CXCL10−/− mice mounted com-
parable IFN-γ and IL-17 recall responses upon antigenic chal-
lenge ex vivo (Fig. 1C and G). Interactions between CXCR3 and
its ligands (CXCL9, CXCL10, and CXCL11) can play a critical
role in the chemotaxis of Th1 cells to the CNS [27]. Paradox-
ically, IFN-γ-producing cells were more prevalent than IL-17-
producing cells in CNSmononuclear fractions from CXCR3−/− and
CXCL10−/−, as well as WT, mice with MOG-induced EAE (Fig. 1D
and H).
Enrichment of IFN-γ producers within the CNS could be sec-
ondary to preferential trafficking, survival, and/or expansion of
Th1 over Th17 cells. If so, the data in Figure 1 would insinuate
that MOG-specific Th1 cells cross the blood–brain barrier and are
retained in the brain and SC by a CXCR3/CXCL10-independent
mechanism. Alternatively, the majority of CNS-infiltrating
IFN-γ-producing T cells could represent transformed Th17 cells
that acquire Th1-like characteristics within the CNSmicroenviron-
ment (the so-called “ex-Th17” cells) [28]. Th17 cells have been
shown to access the CNS via a CCR6-CCL20-dependent pathway,
which could explain the dispensability of CXCR3-CXC chemokine
interactions for the development of IFN-γ-rich neuroinflammatory
infiltrates in MOG-immunized mice [26]. In support of the latter
hypothesis, mRNA for IL-17A, RORγt, and CCL20 was upregu-
lated in the CNS of CXCR3−/−, CXCL10−/−, and WT mice with
EAE (Fig. 1I and J).
CXCR3 signaling is dispensable for the development
and function of encephalitogenic Th1 cells
Next, we sought to directly compare the relative dependence of
MOG-specific Th1 and Th17 cells on CXCR3/ELR− CXC chemokine
interactions for their encephalitogenicity. MOG-primed CXCR3−/−
T cells exhibited similar cytokine profiles to their WT counterparts
following culture under either Th1- or Th17-polarizing conditions
(Fig. 2A). As expected, MOG-primed, IL-23-polarized CXCR3−/−
Th17 cells were as efficient as WT Th17 cells in trafficking to
the CNS and inducing clinical EAE following adoptive transfer
into na¨ıve syngeneic WT hosts (Supporting Information Fig. 1
and Fig. 2B). Surprisingly, IL-12-polarized CXCR3−/− Th1 cells
showed no defect in EAE induction (Fig. 2C). In fact, recipients
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Figure 1. CXCR3−/− and CXCL10−/− mice are susceptible to MOG-induced EAE. WT C57BL/6 and (A) CXCR3−/− or (E) CXCL10−/− mice were actively
immunized with MOG35–55 in CFA and rated for clinical signs of EAE on a daily basis. (B and F) Spleens, draining lymph nodes (dLNs), and spinal
cords (SC) were harvested at (B) day 20 and (F) day 16 postimmunization. The total number of live cells per tissue was counted by Trypan blue
exclusion assay. Splenocyte suspensions were subjected to red blood cell lysis prior to counting. SC mononuclear cells were pooled from each
group (n = 4–6 mice per group) and isolated over a Percoll gradient. (C and G) Cell suspensions were cultured with or without 50 μg/mL MOG35–55
for ELISPOT assay. Background spots (that developed without the addition of antigen) were subtracted to generate the data shown. Data represent
mean +SEM. (D and H) The ratio of MOG-specific IFN-γ producers over MOG-specific IL-17 producers is shown for the indicated tissues. (I, J) In
separate experiments, SCs from MOG35–55-immunized WT C57BL/6 or (I) CXCR3−/− or (J) CXCL10−/− mice were analyzed by real-time RT-PCR. Data
represent fold induction relative to naive SCs. (A–J) Data are shown asmean+SEM of four to sixmice per group from one experiment representative
of three performed. *p < 0.05; **p < 0.01; ***p < 0.001, compared with naı¨ve cords, unpaired Student’s t-test.
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Figure 2. CXCR3 signaling is dispensible for the development and function of encephalitogenic Th1 cells. Ten days after immunization with
MOG35–55 in CFA, draining LN cells were harvested from WT C57BL/6 or CXCR3−/− mice and cultured under conditions favorable to the generation
of Th1 or Th17 cells. (A) Prior to transfer, CD4+ T cells were analyzed for intracellular cytokine expression following mitogenic stimulation.
(B) 2 × 106 WT or CXCR3−/− Th17 cells were injected i.p. into naı¨ve WT C57BL/6 hosts, which were monitored for clinical signs of EAE on a daily
basis. Data are shown as mean ± SEM of n = 5 mice per group from one experiment representative of two independent experiments performed.
(C) 2 × 106 WT or CXCR3−/− Th1 cells were injected i.p. into naı¨ve congenic CD45.1+ WT C57BL/6 hosts and monitored for clinical signs of EAE on
a daily basis. Data are shown as mean ± SEM of n = 4–6 mice per group from one experiment representative of three independent experiments
performed. *p< 0.05; **p< 0.01; ***p< 0.001, compared with recipients ofWT Th1 cells, two-way ANOVAwith repeatedmeasures test. (D) At the end
of the experiment, spinal cord (SC) mononuclear cells were isolated over a Percoll gradient, pooled and analyzed by flow cytometry. The absolute
numbers of CD45.2+ donor cells and CD45.1+ congenic host cells were determined per SC. The histogram shows intracellular IFN-γ expression
by the donor cells in each group (broken line, WT; solid line, CXCR3−/−). (E) WT C57BL/6 or CXCR3−/− or CXCL10−/− mice were immunized with
MOG35–55 in CFA and injected with PT. SCs harvested at the peak of disease were analyzed by real-time RT-PCR. Data represent fold induction
relative to naive SCs and are shown as mean +SEM of n = 3–5 mice per group from one experiment representative of two performed. *p < 0.05;
**p < 0.01; ***p < 0.001, compared with naı¨ve cords, unpaired Student’s t-test. (F) 2 × 106 WT Th1 cells were injected i.p. into naı¨ve WT C57BL/6 or
CXCL10−/− host mice. Hosts were monitored for clinical signs of EAE on a daily basis. Data are shown as mean ± SEM of n = 4–6 mice per group
from one experiment representative of three performed. *p< 0.05; **p< 0.01; ***p< 0.001, compared withWT hosts, two-way ANOVAwith repeated
measures test.
of CXCR3−/− Th1 cells underwent a prolonged disease course
with attenuated remission compared to recipients of WT Th1
cells. CXCR3−/− Th1 cells accumulated in the CNS in comparable
numbers to WT Th1 donor cells, and the majority of CXCR3−/−
donor T cells in the SC were IFN-γ+ (Fig. 2D). CXCL10 is a dom-
inant CXCR3 ligand in the CNS of the EAE models employed in
our studies; C57BL/6 mice do not produce functional CXCL11
protein and CXCL10 is significantly upregulated in the inflamed
CNS of MOG-immunized mice (Fig. 2E). In parallel experiments,
CXCL10−/− and WT hosts exhibited a comparable degree of sus-
ceptibility to EAE mediated by WT Th1-polarized, MOG-specific
effector T cells (Fig. 2F). Similar to WT recipients of CXCR3−/−
Th1 cells, CXCL10−/− recipients of WT Th1 cells experienced a
relatively severe disease course.
CXCR3 blockade does not attenuate
Th1-mediated EAE
Mice that are genetically deficient in an immunological molecule
can develop compensatory pathways as they mature. In order to
investigate the consequence of disrupting CXCR3 interactions in
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Figure 3. CXCR3 blockade does not attenuate Th1-mediated EAE. (A and B) Naı¨ve WT congenic (CD45.1+) recipients of MOG-specific (A) Th1 or (B)
Th17 cells were treated with anti-CXCR3 or anti-CXCL10 antisera, or NRS, every third day from the time of cell transfer to day 15, or not treated at
all. Mice weremonitored daily for clinical signs of EAE. Data are shown asmean ± SEM of n = 5mice per group from one experiment representative
of two performed. (C and D) At the end of the experiment, single-cell suspensions were prepared from spleens (individually) and spinal cords
(pooled per group) of (C) Th1 and (D) Th17 recipients for flow cytometric analysis. The isolated cells were stained for extracellular CD4, CD45.1,
and CD45.2. The frequency of donor cells among total CD4+ T cells is presented as mean +SEM of n = 5 mice per group from one experiment
representative of two performed.
a clinically relevant setting, neutralizing antisera to CXCR3 or
CXCL10, or normal rabbit serum (NRS) was administered to WT
mice following the transfer of encephalitogenic T cells. These same
reagents, administered at the same dose, have been shown to sig-
nificantly reduce CNS infiltration by CD4+ T cells in a C57BL/6
mouse model of demyelinating disease induced by mouse hepati-
tis virus [27, 29]. Consistent with the results we obtained with
knockout mice, neither treatment had a significant impact on the
clinical course of EAE, irrespective of the Th lineage of donor
T cells (Fig. 3A and B). The frequency of donor cells among CNS-
infiltrating T cells was similar between adoptive transfer recipients
that were treated with NRS or either anti-CXCR3 or anti-CXCL10
antisera (Fig. 3C and D).
Discussion
The success of natalizumab and fingolimod in suppressing dis-
ease activity in individuals with relapsing-remitting MS has val-
idated the strategy of modulating trafficking molecules to attain
long-lived clinical remission. However, these agents target adhe-
sion molecules that are widely expressed on leukocytes, thereby
increasing the risk of opportunistic infection [30]. Therefore, there
is still a need to develop drugs that distinguish between pathogenic
and protective leukocytes. Chemokines and their receptors are
candidate pharmaceutical targets for disease modification. Vari-
ability in the patterns of chemokine receptor expression on Th
subsets lends a relatively high degree of selectivity to reagents
that disrupt chemokine signaling. Hence, if a chemokine receptor
is preferentially expressed on autoimmune effector T cells, admin-
istration of a specific antagonist to that receptor may decrease
relapse rates with less of an impact on protective immunity than
currently available drugs.
A potential drawback of therapies with a restricted mechanism
of action is that, despite a favorable safety profile, they might only
be effective in a fraction of patients. Indeed, persons with MS com-
prise a diverse population with regard to clinical course as well
as responsiveness to disease-modifying drugs [31]. At present, no
clinical features or biomarkers have been identified that reliably
predict responsiveness to a particular therapy. Th1 and Th17 effec-
tor cells have both been implicated in the development of MS and
EAE. Adoptive transfer experiments have shown that these sub-
sets employ distinct adhesion, chemotactic and effector molecules
to mediate clinically indistinguishable forms of EAE [23]. In
the animal model, such differences in pathogenic mechanisms
translate into differential efficacy of specific immunomodulatory
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interventions. Collectively, the above observations suggest that the
optimal management of MS will only be realized once strategies
are developed to characterize the immune repertoire of individual
patients and to customize their therapy accordingly.
The goal of the current study was to assess, as a proof of princi-
ple, whether antagonizing a chemokine receptor that is expressed
at high levels on a polarized effector T-cell population is a feasi-
ble approach for the customized treatment of CNS autoimmunity.
CXCR3 is preferentially expressed on encephalitogenic Th1 cells
[13, 32, 33], and on T cells that infiltrate MS and EAE lesions
[4–6,9–11], making it a logical therapeutic target for the suppres-
sion of Th1-mediated inflammatory demyelinating disease. We
found that, even in that special circumstance, blockade of CXCR3,
or neutralization of its primary ligand, had no therapeutic impact
on the clinical course of EAE. Similarly, CXCR3−/− Th1 cells were
not compromised in their ability to transfer clinical EAE. In fact,
WT recipients of CXCR3−/− Th1 cells, or CXCL10−/− recipients of
WT Th1 cells, failed to recover following peak disease to the same
extent as their WT counterparts (Fig. 2C and F). It is possible that
widespread and diffuse parenchymal distribution of effector cells,
as described by Muller et al. in MOG-immunized CXCR3−/− mice
[17], results in increased axonal damage and long-term deficits. Of
note, administration of a mAb specific for CXCR3 was found to be
therapeutically beneficial in a Lewis rat model of EAE induced by
the adoptive transfer of unpolarized myelin basic protein reactive
T cells [10]. As in our study, the investigators did not adminis-
ter Bordetella pertussis toxin (PT) to transfer recipients. The dis-
crepancy between their results and ours further underscores the
heterogeneity of encephalitogenic T cells and reinforces our con-
tention that the importance of a specific molecule as a therapeutic
target is context dependent.
Other laboratories have previously reported that Th17 “sen-
tinel” cells traverse the blood–brain barrier at the inception of
EAE and release vasoactive substances that permit the subsequent
infiltration of Th1 cells [26,34,35]. This raises the possibility that
in our experimental paradigms, neuroinflammation is initiated
by a minor subpopulation of Th17 contaminants within the pool
of IL-12-polarized donor cells. We deem this unlikely since we
were unable to detect IL-17+ cells among IL-12-polarized donor
T cells. Furthermore, we did not detect RORγt transcripts in mRNA
extracted from donor cells immediately prior to adoptive transfer
(data not shown). It has also been reported that CNS expression of
ELR− CXC chemokines leads to the local accumulation of CXCR3+
Tregs [17, 36]. By extension, mice with a disrupted CXCR3/CXC
chemokine pathway could be relatively susceptible to EAE due to
a dearth of Tregs in target organ infiltrates. However, we found no
difference in the percentage of FoxP3+ T cells in the CNS of WT
and CXCL10−/− hosts with Th1-mediated EAE. Similarly, FoxP3+
donor cells occurred at the same frequency in the adoptive recipi-
ents of CXCR3−/− and WT Th1-polarized cells (data not shown).
We believe that the most likely explanation for the dispensabil-
ity of CXCR3/CXC chemokine interactions in the manifestation
of Th1-mediated EAE lies in the complexity of chemokine path-
ways that arise at sites of neuroinflammation. Th1 cells express
CCR2 and CCR5 [33,37], and their respective ligands, CCL2 and
CCL5, are upregulated in the CNS during EAE [38, 39]. Analo-
gous to our findings with CXCR3−/− mice, CCR2−/− and CCR5−/−
mice remain susceptible to EAE [40, 41]. Whether this is due to
the adoption of compensatory trafficking pathways by the single
knockout mice will only be determined by future experiments with
double or triple knockouts. The redundancy of chemokines in the
EAE model is further illustrated by a previous publication showing
that simultaneous blockade of CXCR3 and CXCR4 was therapeu-
tically efficacious in adoptively transferred EAE in comparison to
targeting CXCR3 alone [42].
In conclusion, the strategy of antagonizing individual
chemokine/chemokine receptor interactions in individuals with
MS, including those patients with a skewed effector population,
might be undermined by inherent redundancies in chemokine net-
works. The ideal therapeutic target would be a molecule that is
exclusively expressed on autoimmune effector cells and that is
critical for pathogenicity. Until such a molecule is identified, the
treatment of autoimmune disease will have to balance therapeutic
effectiveness against the untoward consequences of immunosup-
pression.
Materials and methods
Mice
About 8- to 12-week-old C57BL/6 and CD45.1 congenic B6
Ly5.2/Cr mice were obtained from NCI Frederick (Frederick, MD,
USA). Cxcr3−/− mice were provided by C. Gerard, the gener-
ation and characterization of which were described previously
[43]. CXCL10−/− mice were obtained from The Jackson Labora-
tory (Bar Harbor, ME, USA). Mice were housed in micro-isolator
cages under specific pathogen-free, barrier facility conditions. All
procedures were conducted in strict accordance with protocols
approved by the University of Michigan Committee on Use and
Care of Animals.
Induction and treatment of EAE
Active induction of EAE involved s.c. injection of 100 μg MOG35–55
MEVGWYRSP-FSRVVHLYRNGK (Biosynthesis, Lewisville, TX,
USA) in CFA (Difco, Detroit, MI, USA) containing 4 mg/mL heat-
killedMycobacterium tuberculosis H37Ra (Difco). Each mouse also
received 300 ng of Bordetella PT(List Biological Laboratories)
i.p. on day 0 and 2 postimmunization. For passive induction,
mice were immunized as above, but without administration of
PT. Ten days postimmunization, a single-cell suspension was pre-
pared from pooled draining inguinal, axillary, and brachial LNs
and passed through a 70 μm cell strainer (BD Falcon, Franklin
Lakes, NJ, USA). LN cells were cultured in vitro for 4 days with
MOG35–55 under conditions favorable to the generation of Th1 cells
(rmIL-12, 6 ng/mL; rmIFN-γ, 2 ng/mL; anti-IL-4 (clone 11B11),
10 μg/mL) or Th17 cells (rmIL-1α, 10 ng/mL; rmIL-23, 8 ng/mL;
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anti-IL-4 (clone 11B11), 10 μg/mL; anti-IFN-γ (clone XMG1.2)
10 μg/mL). After 4 days culture, LN cells were collected and 2 ×
106 CD4+ T cells injected i.p. in sterile PBS. Mice were observed
daily for signs of EAE and the severity of neurological impairment
rated as follows: 0, no discernible deficit; 1, limp tail; 2, impaired
gait and/or ability to flip over from a supine position; 3, partial
hindlimb paralysis; 4, total hindlimb paralysis; 5, moribund.
Rabbit polyclonal antisera specific for mouse CXCR3 and
CXCL10 were provided by Dr. Thomas Lane, the generation of
which has previously been described [44]. These reagents have
been shown to be specific for mCXCR3 and mCXCL10 and do not
cross-react with a panel of other human and murine recombinant
cytokines [27,29,44]. They have been shown to block CD4+ T-cell
infiltration in vivo [27,29,44]. Experimental groups of mice were
injected i.p. with 0.5 mL anti-mCXCR3 or anti-mCXCL10 every
third day from d 0 to d 15 post-T-cell transfer. NRS from the same
preinoculated rabbits was used as a control.
ELISPOT assays
Antigen-specific cytokine production was determined in spleen
and dLN cells and mononuclear cells isolated by Percoll density
centrifugation from the pooled SCs of mice perfused with PBS,
following culture for 24 h in 96-well filtration plates (Millipore),
with or without 50 μg/mLMOG35–55. Antibodies from eBioscience
were anti-IL-17 (TC11–18H10), biotinylated anti-IL-17 (TC11–
8H4), IFN-γ (AN18), and biotinylated anti-IFN-γ (R4–6A2).
Streptavidin–alkaline phosphatase (Southern Biotech) and an
alkaline phosphatase substrate kit (Vector Laboratories) were
used to identify trapped cytokine. Spots were counted using
the CTL ImmunoSpot Analyzer (Cellular Technology) with
ImmunoSpot software, and the number of spots in the medium
only wells subtracted.
Real-time RT-PCR
RNA was harvested from whole SC using the Trizol (Invitro-
gen)/chloroform method followed by RT into cDNA using the
High-Capacity cDNA Reverse Transcription Kit (Applied Biosys-
tems). Primers and probes were designed using Beacon Designer
and synthesized by Integrated DNA Technologies. Samples were
analyzed on an iCycler PCR machine (Bio-Rad Laboratories). Data
were normalized to the endogenous control β-actin and expressed
as fold increase over SCs from na¨ıve mice.
Intracellular cytokine staining and flow cytometry
Splenocytes, mononuclear cells isolated by Percoll density
centrifugation from the pooled SCs of mice perfused with PBS,
or polarized dLN cells following culture were activated (2 ×
106 cells/mL) with PMA (50 ng/mL; Sigma) and ionomycin
(2 μg/mL; Sigma), in the presence of brefeldin A (5 μg/mL),
for 6 h at 37◦C. Cells were washed and blocked with Fc block
(clone 2.4G2; 50 μg/mL) before extracellular staining with
fluorochrome-conjugated antibodies for CD3, CD4, CD45.1,
and CD45.2 (eBioscience). Cells were then fixed with 4%
paraformaldehyde, permeabilized with saponin (Sigma), and
stained intracellularly with fluorochrome-conjugated antibodies
for IL-17 or IFN-γ (eBioscience). Flow cytometric analysis was per-
formed using a FACSCanto II flow cytometer (Becton–Dickinson)
and analyzed with FloJo software (Tree Star, Inc.), with gating
set on isotype controls. Absolute numbers of donor and host cells
were determined by multiplying the total cell count per tissue
by the frequency of congenic cells among the total CD4+ T-cell
population, within the live cell gate.
Statistical analysis
Statistical analyses were performed using GraphPad Prism sta-
tistical analysis software. Group differences were analyzed by
unpaired, two-tailed Student’s t-test, while a two-way ANOVA
with repeated measures was applied when comparing different
experimental groups over time. p-values of 0.05 or less were con-
sidered significant.
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